Category: Pharmaceuticals
-
![Filament Health (FH.NEO) Leading the way in Natural Psychedelics. But Is it a Good Long Term Investment?]()
Filament Health (FH.NEO) Leading the way in Natural Psychedelics. But Is it a Good Long Term Investment?
In this episode, we take a look at a company that’s on a mission to get safe, natural psychedelics into the hands of everyone who needs them, as soon as possible. Filament Health (FH.NEO) is an exclusively natural psychedelic drug development company and received the first-ever psilocybin extraction and standardization patent for a public company…
-
![Valeo Pharma(VPH), complicated sector but simple business model]()
Valeo Pharma(VPH), complicated sector but simple business model
Stock Performance From the chart below it seemed like the Valeo Pharma (“VPH”) shareholders have had quite a wild ride over the last few years. Starting in 2019 the stock was trading at $0.72 per share, but by mid-August, the stock had dropped by almost 50% to around $0.30 per share before it did nothing…
-
![Valeo Pharma (VPH.C) CEO Steve Saviuk talks specialty pharma opportunity (Ep4) Chris’ Corner]()
Valeo Pharma (VPH.C) CEO Steve Saviuk talks specialty pharma opportunity (Ep4) Chris’ Corner
Steve Saviuk, president and CEO of Valeo Pharma (VPH.C), talks about the transformative partnerships with international players such as Novartis and members of the Canadian Healthcare Industry, that allow the company to bring leading innovative products to the Canadian market. Tune in!
-
![Undervalued Valeo Pharma (VPH.C) and their asthma inhalers may be 2021’s shiniest hidden gem]()
Undervalued Valeo Pharma (VPH.C) and their asthma inhalers may be 2021’s shiniest hidden gem
There’s nothing more terrifying than watching a loved one pause, clutch their throat and start gasping for air. The first time it happens provokes the mad scramble, as she points at her purse and mimes the universal L-shaped hand pattern for an asthma inhaler. She sits while you go digging through spent candy wrappers, old…
-
Cybin (CYBN.NEO): Grown up approach to psychedelics brings half billion valuation… so far
Back in January of this year, we told you about a psychedelics company that was going to come at that sector like many had talked about, but few had achieved. Their angle? Be a biotech company. Don’t dick about with fakey business plans or black velvet paintings of Elvis. No Jamaican B&Bs dressed up as…
-
![Bioasis Technologies (BTI.V) stock is on the move – following scientific validation of xB3 platform]()
Bioasis Technologies (BTI.V) stock is on the move – following scientific validation of xB3 platform
Bioasis Technologies’ (BTI.V) xB3 platform is designed to deliver therapeutics across the blood brain barrier. BTI’s proprietary tech is relevant to the treatment of brain cancers and neurodegenerative diseases. Investing in small-cap pharmaceutical companies requires patience. Not every product in the pipeline pans out. Some trials have disappointing outcomes. Many investors can’t handle the zigs…
-
![Revive Therapeutics (RVV.C) incredible patent-portfolio explained]()
Revive Therapeutics (RVV.C) incredible patent-portfolio explained
Revive Therapeutics (RVV.C) is a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders. RVV holds 13 patents (issued and provisional) for covid-treatment, gout, drug delivery systems, cannabidiol and psilocybin. “We are proud of the IP portfolio that we’ve generated,” stated Michael Frank, CEO of Revive…
-
![Medexus Pharmaceuticals (MDP.T) gets the Health Canada official nod to commercialize treosulfan]()
Medexus Pharmaceuticals (MDP.T) gets the Health Canada official nod to commercialize treosulfan
Medexus Pharmaceuticals (MDP.T) received Health Canada’s Notice of Compliance to commercialize treosulfan today, according to a press release. Treosulfan will be sold in Canada using the brand name Trecondyv®. It’s used in combination with another drug called fludarabine as part of a conditioning treatment prior to allogeneic hemapoietic stem cell transplantation. The treatment clears the…
-
![Bioasis Technologies (BTI.V) and The Lind Partners come to financing deal]()
Bioasis Technologies (BTI.V) and The Lind Partners come to financing deal
Bioasis Technologies (BTI.V) entered into a convertible security financing earlier this week with New-York based investment management firm, Lind Global Macro Fund, a subsidiary of The Lind Partners, according to a press release. The terms of the agreement give Bioasis the ability to issue convertible securities up to $10 million with proceeds going to general…
-
![Bioasis Technologies (BTI.V) and the painful price of private sector science]()
Bioasis Technologies (BTI.V) and the painful price of private sector science
Science isn’t cheap. Overhead for scientific based companies is usually sky high for a reason. It’s not just keeping the lights on, or making sure everyone from the CEO to the janitorial staff get paid on time, although that’s part of it. It’s revolving costs in equipment, other forms of capital—like human capital—the average science…
